Research programme: tuberculosis therapeutics - Lilly TB Drug Discovery Initiative

Drug Profile

Research programme: tuberculosis therapeutics - Lilly TB Drug Discovery Initiative

Alternative Names: BIKAKEN; CPZEN-45

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Microbial Chemistry; Microbial Chemistry Research Foundation; Summit plc
  • Developer Eli Lilly
  • Class Nucleosides; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA (Inhalation)
  • 24 Aug 2017 Infectious Disease Research Institute and Zhejiang Hisun Pharmaceutical agree to co-develop CPZEN 45 for tuberculosis
  • 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top